GAMMA Investing’s Catalyst Pharmaceutical CPRX Stock Holding History

GAMMA Investing’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-4,150	Closed	-$130K	–	4342
2026 Q2	$130K	Buy	4,150 +639	+18%	+$18.9K	﹤0.01%	1607
2026 Q1	$86.9K	Buy	3,511 +944	+37%	+$22.5K	﹤0.01%	1789
2025 Q4	$59.9K	Sell	2,567 -40	-2%	-$891	﹤0.01%	1950
2025 Q3	$51.4K	Sell	2,607 -569	-18%	-$11.7K	﹤0.01%	1971
2025 Q2	$68.9K	Buy	3,176 +385	+14%	+$9.09K	﹤0.01%	1697
2025 Q1	$67.7K	Buy	2,791 +579	+26%	+$13K	0.01%	1566
2024 Q4	$46.2K	Buy	2,212 +434	+24%	+$9.32K	﹤0.01%	1718
2024 Q3	$35.3K	Buy	1,778 +681	+62%	+$12.6K	﹤0.01%	1734
2024 Q2	$17K	Sell	1,097 -845	-44%	-$13.2K	﹤0.01%	1959
2024 Q1	$31K	Buy	1,942 +819	+73%	+$12.3K	0.01%	1345
2023 Q4	$16.2K	Buy	+1,123	New	+$15.4K	﹤0.01%	1632

Other funds holding CPRX

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

GAMMA Investing's CPRX Position: Q3 2026 in Review

GAMMA Investing sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 4,150 shares — an estimated $130K sold.

GAMMA Investing first reported a position in CPRX in Q4 2023 and held it in 11 quarters. The position peaked at $130K in Q2 2026. 1 fund tracked by Wall St. Rank holds CPRX as of Q3 2026.

GAMMA Investing reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
GAMMA Investing sold 4,150 Catalyst Pharmaceutical shares in Q3 2026, an estimated $130K.
GAMMA Investing first reported a position in Catalyst Pharmaceutical in Q4 2023 and held it in 11 quarters.
GAMMA Investing's Catalyst Pharmaceutical position peaked at $130K in Q2 2026.
1 fund tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.